Navigation Links
Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
Date:9/28/2007

CALGARY, AB, --- September 28, 2007 - Oncolytics Biotech Inc. (Oncolytics) (TSX:ONC, NASDAQ:ONCY) announced that an oral presentation covering interim results from a U.K. Phase Ia/Ib combination REOLYSIN and radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented at the National Cancer Research Institute (NCRI) conference on October 2, 2007 in Birmingham, U.K. The presentation, entitled Biological Approaches to Radiosensitisation: Viruses, Gene Therapy and Novel Radiosensitisers will be presented by Dr. Kevin Harrington of The Institute of Cancer Research, London and one of the principal investigators for the trial. The conference runs from September 30 through October 3, 2007 in Birmingham, U.K.

We are very pleased with the results of this trial to date, said Dr. Brad Thompson, President and CEO of Oncolytics. We continue to evaluate the data and look forward to announcing final results.

To date, 22 patients have been treated with 15 having completed the study. Five patients withdrew from the study, and two patients are still on study.

A total of 11 patients in the Ia portion of the trial received two intratumoural treatments of REOLYSIN at dosages of 1x108, 1x109, or 1x1010 TCID50 with a constant localized radiation dose of 20 Gy given in five fractions. Of these 11 patients, three patients (oesophageal, squamous skin carcinoma and squamous cell scalp) experienced significant partial responses.

One month following treatment, the oesophageal patient experienced a 28.5% reduction in the target tumour, with stable disease noted in four, non-treated tumours. At two and three months, the target tumour had shrunk 64%, with stable disease continuing in the four non-treated tumours, including a 15% volume reduction in non-treated mediastinal disease that was maintained for more than six months. The squamous skin cancer patient experienced a 50% reduction in the target tumour, as well as stable
'/>"/>

Contact: Cathy Ward
cathy.ward@oncolytics.ca
403-670-7370
Oncolytics Biotech Inc.
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Biotechnology industry expected to grow into a three billion dollar industry by 2002
2. Biotechnology on the lead
3. Panacea Biotech To Market Anthrax Vaccine
4. Commercialization of Biotech Discoveries, An Encouragement For Researchers
5. Biotech drug causing anemia-EPREX
6. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
7. Biologicals Transfer Proposal between US and Indian Biotechnology
8. Finland and India to interact and cooperate in the filed of telemedicine and biotechnology
9. Vical Biotech and NIH jointly develops HIV vaccine
10. Biotechnology Initiatives Planned In Hyderabad
11. Biotech Osiris to go public
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2008)...y 21 /PRNewswire-FirstCall/ -- Aflac Incorporated,...presentation at the Sanford,C. Bernstein & Co., LL...nce,2008., President and Chief Financial Officer ...ted, and he is scheduled to make a presentation on...orated presentation, Mr.,Cloninger will discuss th...
(Date:5/21/2008)...d SILVER SPRING, Md., May 21 /PRNewswire-USNewswir... (ADAA),( http://www.adaa.org ) and The HealthCent... announced that ADAA will join,HealthCentral,s gro...and,health experts dedicated to helping people suf... advice and support they need to cope with the,con...
(Date:5/21/2008)...s 1st quarter profit, enhanced operations and new ...ELES, May 21 /PRNewswire-FirstCall/ -- InstaCare C...butor of at-home testing diagnostics,for the chron...eveloper of,patent-pending technologies for e-heal...s for the first quarter period-ended March 31, 200...
(Date:5/21/2008)... Adverse Events in TORCH Showed Frequency Highest ...ONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRN...500/50 (fluticasone propionate and,salmeterol inha...er of,cardiovascular adverse events compared to ot...from the TOwards a Revolution in COPD Health,(TORC...
Breaking Medicine News(10 mins):Health News:Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3
...access to a high-profile detainee at Guantanamo Ba...n //techniques "national security secrets" whose r...e Washington Post reported Saturday.The US governm...must not be allowed to talk about the interrogatio...
...system to control HIV infection appears to depend ... molecules// called HLA Class I that have been inh...in those molecules display to the T lymphocytes th... the November issue of PLOS Medicine, researchers ...
...nts who behave in an unbecoming manner, and will n...an NHS hospital to punish patients// that disrupt .... The Royal Bolton hospital in Greater Mancheste...vernment to check violent behavior in hospitals. T...
...ng against time to prevent HIV, the virus that cau...the nation witnessing a rise in// the number of pr...s Public Health Division has launched a three-year...doms and voluntary testing of blood to prevent HIV...
Other Medicine News:Health News:Genes determine the capacity to fight HIV in early stages 2Health News:Genes determine the capacity to fight HIV in early stages 3Health News:HIV/AIDS Epidemic Scare In Bhutan 2
(Date:5/21/2008)... products highlight Watson,s commitment to urology...T, ORLANDO, Fla., May 21 /...ading specialty pharmaceutical company, announced,...n two Phase 3 products at,the American Urological ...e,a cardiac safety trial involving silodosin, an i...
(Date:5/21/2008)...N.J., May 21 /- Genta,Incor...multiple abstracts,featuring its lead oncology pro...of the American Society of Clinical Oncology (ASCO...acts include the following:, -- Initial Phase 1 ...an oral gallium-containing Compound. Poster #...
(Date:5/21/2008)...t American Urological Association Annual Meeting -...irstCall/ -- Researchers,from Dendreon Corporation...,demonstrating the potential of D-3263, Dendreon,s... Trp-p8 (a transmembrane cation channel protein al...erplasia (BPH)., The abstract (#2041), "Preclinic...
(Date:5/20/2008)...echnologies received positive results of nine mont...and Supralimus. The results unveiled during ..., India, May 20 /- Sahajanand Medical...ng developer and manufacturer of,drug-eluting sten...ve,randomized nine months results of PAINT trial ...
Breaking Medicine Technology:Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 2Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 3Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 4Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 5Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 6Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology 2Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology 3Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 2Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 3Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 4Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents 2Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents 3Full Year 2007 Results Date Notification 21 February 2008 3232 1Full Year 2007 Results Date Notification 21 February 2008 3232 2Surgery improves quality of life for children with sleep apnea 11679 1Surgery improves quality of life for children with sleep apnea 11679 2Surgery improves quality of life for children with sleep apnea 11679 3Old dogs 3A Prior knowledge affects how consumers accept new information 11676 1Old dogs 3A Prior knowledge affects how consumers accept new information 11676 2National Lt Governors Association Endorses HERO Campaign 3B 1st National Association of State Elected Officials Supporting Grassroots Designated Driv 11673 1National Lt Governors Association Endorses HERO Campaign 3B 1st National Association of State Elected Officials Supporting Grassroots Designated Driv 11673 2
... results report no new stent thrombosis after two ...s., and BARCELONA, Spain, May 22, 2007,/PRNewswire...,announced four-year follow-up data from its TAXUS... safety and efficacy benefits,associated with a mo...(TM) paclitaxel-eluting stent system -- which is n...
...LONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Profe...lbourne, Australia, on,Tuesday presented positive ...nical trial at the EuroPCR meeting in Barcelona, S...rdiac events and no,protocol-defined stent thrombo...avor(R) Resolute drug-eluting stent system with ne...
Other Medicine Technology:Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3Medtronic Announces Positive Nine-Month Results for Endeavor,Resolute Next Generation Drug-Eluting Stent at EuroPCR 2Medtronic Announces Positive Nine-Month Results for Endeavor,Resolute Next Generation Drug-Eluting Stent at EuroPCR 3
Malaria Pf. Assay Range
An immunochromatographic test for detection of 4 species of Plasmodium antigen ( P. falciparum , P. vivax , P. malariae , P. ovale ) in whole blood.
192 Test HRP-II Enzyme Immunoassay for the presence of Plasmodium falciparum infection.
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)
Medicine Products: